Equities Analysts Set Expectations for ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Esperion Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will post earnings of $0.05 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $8.00 target price on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.28) per share.

ESPR has been the topic of several other research reports. JMP Securities reissued a "market outperform" rating and issued a $7.00 price target on shares of Esperion Therapeutics in a report on Thursday. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They issued a "neutral" rating and a $4.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $6.00 target price on shares of Esperion Therapeutics in a report on Friday, December 13th. StockNews.com lowered shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $7.25.

Esperion Therapeutics Stock Down 5.5 %

Esperion Therapeutics stock traded down $0.12 on Wednesday, hitting $2.08. The company's stock had a trading volume of 6,577,948 shares, compared to its average volume of 5,229,817. The firm has a market cap of $409.84 million, a P/E ratio of -3.25 and a beta of 1.03. The company has a fifty day moving average price of $2.46 and a 200-day moving average price of $2.18. Esperion Therapeutics has a one year low of $1.58 and a one year high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The company had revenue of $51.63 million for the quarter, compared to analysts' expectations of $55.44 million. During the same period in the prior year, the firm posted ($0.37) EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ESPR. Rhumbline Advisers lifted its position in Esperion Therapeutics by 6,560.6% during the 2nd quarter. Rhumbline Advisers now owns 252,038 shares of the biopharmaceutical company's stock worth $560,000 after buying an additional 248,254 shares in the last quarter. American Century Companies Inc. acquired a new position in Esperion Therapeutics during the 2nd quarter valued at about $50,000. Xponance Inc. acquired a new position in Esperion Therapeutics during the 2nd quarter valued at about $28,000. Marshall Wace LLP lifted its position in Esperion Therapeutics by 94.2% during the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company's stock valued at $9,554,000 after purchasing an additional 2,087,635 shares during the period. Finally, Deerfield Management Company L.P. Series C acquired a new stake in shares of Esperion Therapeutics in the 2nd quarter valued at approximately $148,000. Institutional investors and hedge funds own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.